# Edinburgh Research Explorer

## Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21

# Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21

**Albert Tenesa**[1,31], **Susan M Farrington**[1,31], **James GD Prendergast**[1], **Mary E Porteous**[2], **Marion Walker**[1], **Naila Haq**[1], **Rebecca A Barnetson**[1], **Evropi Theodoratou**[1,3], **Roseanne Cetnarskyj**[2], **Nicola Cartwright**[1], **Colin Semple**[1], **Andrew J Clark**[1], **Fiona JL Reid**[4], **Lorna A Smith**[4], **Kostas Kavoussanakis**[4], **Thibaud Koessler**[5], **Paul DP Pharoah**[5], **Stephan Buch**[6,7], **Clemens Schafmayer**[7,8], **Jürgen Tepel**[6,8], **Stefan Schreiber**[7,9], **Henry Völzke**[10], **Carsten O Schmidt**[10], **Jochen Hampe**[6], **Jenny Chang-Claude**[11], **Michael Hoffmeister**[12], **Hermann Brenner**[12], **Stefan Wilkening**[13], **Federico Canzian**[13], **Gabriel Capella**[14], **Victor Moreno**[15], **Ian J Deary**[16], **John M Starr**[17], **Ian PM Tomlinson**[18], **Zoe Kemp**[18], **Kimberley Howarth**[18], **Luis Carvajal-Carmona**[18], **Emily Webb**[19], **Peter Broderick**[19], **Jayaram Vijayakrishnan**[19], **Richard S Houlston**[19], **Gad Rennert**[20], **Dennis Ballinger**[21], **Laura Rozek**[22], **Stephen B Gruber**[22], **Koichi Matsuda**[23], **Tomohide Kidokoro**[23], **Yusuke Nakamura**[23], **Brent W Zanke**[24,25,26], **Celia MT Greenwood**[24,27,28], **Jagadish Rangrej**[18,27], **Rafal Kustra**[24], **Alexandre Montpetit**[29], **Thomas J Hudson**[24,25], **Steven Gallinger**[24,30], **Harry Campbell**[1,3], and **Malcolm G Dunlop**[1]

[1]Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and MRC Human Genetics Unit, Edinburgh EH4 2XU, UK

[2]Clinical Genetics Department, Western General Hospital, Edinburgh EH4 2XU, UK

[3]Public Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK

[4]Edinburgh Parallel Computing Centre, University of Edinburgh, Edinburgh EH9 3JZ, UK

[5]Cancer Research UK Laboratories, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK

Correspondence should be addressed to M.G.D. (Malcolm.Dunlop@hgu.mrc.ac.uk)..
[31]These authors contributed equally to this work.

[6]Department of General Internal Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Schittenhelmstraße 12, 24105 Kiel, Germany

[7]POPGEN Biobank, University Hospital Schleswig-Holstein, Campus Kiel, Schittenhelmstraße 12, 24105 Kiel, Germany

[8]Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, 24105 Kiel, Germany

[9]Institute for Clinical Molecular Biology, University Hospital Schleswig-Holstein, Campus Kiel, Schittenhelmstraße 12, 24105 Kiel, Germany

[10]Institute for Community Medicine, University Hospital Greifswald, Walther Rathenau Str. 48, 17487 Greifswald, Germany

[11]Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

[12]Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

[13]Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany

[14]Translational Research Laboratory, IDIBELL-Catalan Institute of Oncology and University of Barcelona, L'Hospitalet, Barcelona 08907, Spain

[15]Bioinformatics Unit, IDIBELL-Catalan Institute of Oncology and University of Barcelona, L'Hospitalet, Barcelona 08907, Spain

[16]Department of Psychology, University of Edinburgh, Edinburgh EH8 9JZ, UK

[17]Geriatric Medicine, University of Edinburgh, Royal Victoria Hospital, Edinburgh EH4 2DN, UK

[18]Molecular and Population Genetics Laboratory, Cancer Research UK London Research Institute, London WC2A 3PX, UK

[19]Section of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK

[20]CHS National Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion x2013 Israel Institute of Technology, Haifa, Israel

[21]Perlegen Sciences, Mountain View, California 94043, USA

[22]Departments of Internal Medicine, Epidemiology and Human Genetics, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA

[23]Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan

[24]Cancer Care Ontario, 620 University Avenue, Toronto, Ontario M5G 1L7, Canada

[25]Ontario Institute for Cancer Research, 101 College Street, Toronto, Ontario M5G 2L7, Canada

[26]The University of Ottawa, Faculty of Medicine, Division of Hematology, 501 Smythe Road, Ottawa K1H 8L6, Canada

[27]Genetics and Genome Biology, Hospital for Sick Children, 15-703 TMDT East, 101 College Street, Toronto, Ontario M5G 1L7, Canada

[28]University of Toronto, Department of Public Health Sciences, Health Sciences Building, 155 College Street, Toronto, Ontario M5T 3M7, Canada

[29]The McGill University and Genome Quebec Innovation Centre, 700 Dr. Penfield Ave., Montreal, Quebec H3G 1A4, Canada

[30]Samuel Lunenfeld Research Institute, Mount Sinai Hospital and University of Toronto, 600 University Avenue, Toronto, Ontario M5G 1×5, Canada

## Abstract

In a genome-wide association study to identify loci associated with colorectal cancer (CRC) risk, we genotyped 555,510 SNPs in 1,012 early-onset Scottish CRC cases and 1,012 controls (phase 1.) In phase 2, we genotyped the 15,008 highest-ranked SNPs in 2,057 Scottish cases and 2,111 controls. We then genotyped the five highest-ranked SNPs from the joint phase 1 and 2 analysis in 14,500 cases and 13,294 controls from seven populations, and identified a previously unreported association, rs3802842 on 11q23 (OR = 1.1; $P = 5.8 \times 10^{-10}$), showing population differences in risk. We also replicated and fine-mapped associations at 8q24 (rs7014346; OR = 1.19; $P = 8.6 \times 10^{-26}$) and 18q21 (rs4939827; OR = 1.2; $P = 7.8 \times 10^{-28}$). Risk was greater for rectal than for colon cancer for rs3802842 ($P < 0.008$) and rs4939827 ($P < 0.009$). Carrying all six possible risk alleles yielded OR = 2.6 (95% CI = 1.75-3.89) for CRC. These findings extend our understanding of the role of common genetic variation in CRC etiology.

Colorectal cancer (CRC) is the third most common cancer and fourth-leading cause of cancer death worldwide. Lifetime risk in Western European and North American populations is around 5%. Both genetic and environmental factors contribute to disease etiology, with about one-third of disease variance attributed to inherited genetic factors[1]. Until very recently, the defined genetic contribution to CRC comprised rare, high-penetrance variants in a few genes (DNA mismatch repair genes[2], *APC, SMAD4, BMPR1A* and *MUTYH*[3]). However, recent association studies have shown that common genetic variation in the 8q24 (refs. [4-6]) and 18q21 (*SMAD7*)[7] regions also contribute to CRC risk. To explore the role of common genetic variation in CRC etiology, we undertook a comprehensive, phased-design genome-wide association scan (GWAS), capitalizing on Scottish population characteristics. We selected early-onset cases for the genome-wide scan on the premise that these may be enriched for genetic contribution and so would provide enhanced power to detect associations. Controls were matched for age, sex and area of residence in phases 1 and 2.

In phase 1, we genotyped 1,012 early-onset CRC cases, comprising the youngest 10th percentile of CRC age distribution in Scotland, and matched controls using Illumina HumanHap300 and HumanHap240S arrays. We analyzed genotype data using a likelihood ratio test (LRT)[8] with 2 degrees of freedom (genotypic model) to account for additive and dominant effects. Empirical significance thresholds were obtained by permuting case-control status 10,000 times[9]. For each permutation, we retained the largest test statistic from each chromosome and used it across all chromosomes to obtain chromosome-wise (Supplementary Table 1 online) and genome-wide significance thresholds (Supplementary Fig. 1 online). Phase 1 test statistics with 5% empirical genome-wide significance thresholds are shown in Supplementary Figure 2 online; none of the SNPs reached genome-wide significance (nonminally $P = 1.12 \times 10^{-7}$). There was no overall inflation of the test statistic ($\lambda = 1.003$), providing reassurance that systematic confounding factors are unlikely (Supplementary Fig. 3 online). Other process quality control measures are described in the **Supplementary Note** online.

From analysis of phase 1 data, we ranked SNPs by test statistic and selected the top 15,008 SNPs ($P < 0.0272$) for further analysis in phase 2. We determined the number of SNPs

empirically, taking into account practical and financial constraints. We genotyped these 15,008 SNPs in 2,057 cases and 2,111 controls using the Illumina iSelect platform. After accounting for quality control measures (**Supplementary Note**), we included 13,450 SNP genotypes from 2,024 cases and 2,092 controls in the analysis. Joint analysis of phase 1 and 2 data again showed that none of the SNPs reached the genome-wide significance threshold obtained by permutation in phase 1 (Supplementary Fig. 4 and Supplementary Table 2 online). We estimated the *Q* value[10] of each test (proportion of false positives incurred when the test is called significant) using phase 2 *P* values, and estimated the false-discovery rate to be approximately 40% for the top 300 ranked SNPs (Supplementary Fig. 5 online).

We took the five top-ranked SNPs from joint analysis of phase 1 and 2 data, equivalent to an empiric threshold of $P < 10^{-5}$, for further analysis. In rank order by *P* value, the top SNPs in the combined phase 1 and 2 data were rs7014346 (8q24), rs4939827 (18q21), rs6533603 (4q25), rs3802842 (11q23.1) and rs9951602 (18q23). Unadjusted OR estimates using binary logistic regression in an additive genetic model are presented in Supplementary Table 2. rs7014346 (LRT = 26.64) reached chromosome-wise significance ($P < 0.05$), further replicating and refining the previous findings[4-6] on the risk locus at 8q24. rs4939827 (LRT = 25.61) is located in intron 3 of *SMAD7*, replicating a recently reported association between this locus and CRC[7].

As the causative variants are unknown for rs7014346 (8q24) and rs4939827 (18q21), we undertook fine mapping by tagging all polymorphic HapMap CEU SNPs around these loci in phase 2 individuals (tagSNPs with $r^2 = 1$ within the interval 50 kb on either side of the interval defined by rs7014346 and rs10505477 on 8q24, and of rs4939827 and rs12953717 on 18q21). Linkage disequilibrium (LD) plots for the 8q24, 18q23 and 11q23.1 regions are shown in Supplementary Figure 6 online. We used data for 94 SNPs successfully genotyped at 8q24 and 96 SNPs at 18q23 for fine mapping of the respective regions (Fig. 1). The association signal drops off sharply on either side of both rs7014346 and rs4939827. Next, we analyzed information from HapMap using IMPUTE[11] for the 11q, 8q and 18q regions to estimate SNP genotypes that we did not type. SNPTEST was used to test for associations under a genotypic model. These analyses (Supplementary Fig. 7 online) show that rs7842552 is the top-ranking imputed SNP at the 8q24 locus ($P = 3.84 \times 10^{-7}$), rs4939827 remains the top-ranking SNP at 18q21 ($P = 1.6 \times 10^{-6}$) and rs3802842 indicates the peak of association at the 11q locus. Resequencing, tumor loss-of-heterozygosity (LOH) analysis and expression studies of genes within the regions delineated by fine mapping at 8q24 and 18q21 provided no additional insight into pathogenicity (**Supplementary Note**).

In phase 3, we genotyped eight additional independent case-control collections and tested for differences between populations. Genotyping was done using Taqman, Sequenom or Invader technology. Subjects were from Scotland, England (Cambridge), Canada (Ontario), Germany (Kiel and Heidelberg), Spain (Barcelona), Japan (Tokyo) and Israel (Haifa), comprising a total of 14,500 cases and 13,294 controls (Table 1). In a meta-analysis of all data to estimate pooled genetic effects (Table 2 and Fig. 2), we found that three of the five top-ranked associations replicated in phase 3 (rs7014346 on 8q24, rs4939827 on 18q21 and rs3802842 on 11q23), in agreement with our false-discovery rate estimate. Genotype counts and risk allele frequencies across populations for the five top-ranked SNPs are shown in Supplementary Table 3 online. We also tested for association at seven additional genotyped SNPs close to the replicated loci (Supplementary Tables 4 and 5 online).

rs7014346 is located on 8q24 and is in high linkage disequilibrium with SNPs that we previously reported (rs10505477 and rs6983267)[4]. However, rs7014346 gave the maximum association signal in the Scottish phase 1 and 2 data. rs7014346 is 3 kb upstream of *POU5F1P1* and within intron 6 of the gene *DQ515897*. The association was independently

replicated in all but the Spanish subjects (Supplementary Table 4) giving a combined $P = 8.6 \times 10^{-26}$. The lack of association in the Spanish cohort is most likely due to the small sample size, as there was no significant heterogeneity for rs7014346 across populations, and stratification tends to increase false positives rather than false negatives. Logistic regression analysis of the combined data showed that a genotypic model fit the data significantly better ($P = 0.02$) than an additive genetic model (Supplementary Table 6 online). Meta-analysis of the pooled data (Table 2 and Fig. 2) yielded ORs for populations of European ancestry of 1.25 (95% CI = 1.18-1.32) for AG and 1.38 (95% CI = 1.28-1.48) for AA genotypes. rs7014346 showed the peak association signal because rs7842552, identified by IMPUTE fine mapping, did not reach the same level of statistical support as rs7014346, and there was significant heterogeneity across study populations ($P = 0.026$).

rs4939827 is located within intron 3 of *SMAD7* on chromosome 18q21. The combined *P* value for association with CRC was $7.77 \times 10^{-28}$ (OR = 1.20). There was no heterogeneity among sample sets ($P = 0.34$; Table 2). The association replicated in all case-control collections individually, except the Spanish set again and the Scottish phase 3 samples (Fig. 2 and Supplementary Table 4). There was no evidence against an additive model for this SNP (Supplementary Table 6).

rs3802842 is located within a gene-rich region of chromosome 11q23, which adds complexity to attempts at identifying the causative variant. Within 100 kb of rs3802842, there are four ORFs (*LOC120376, FLJ45803, C11orf53* and *POU2AF1*) and a sequence (rs12296076) identified as a polymorphic binding site target for miRNAs (see URLs section below) in high linkage disequilibrium. Of note, rs7014346 and rs3802842 were both close to genes encoding POU transcription factors. Hence, we genotyped five additional SNPs around rs3802842, notwithstanding that some SNPs showed only moderate statistical support ($P < 0.03$). However, after genotyping in multiple sample collections, we found that rs3802842 remained the best-supported SNP (Table 2). We observed substantial population-specific differences in risk at the 11q23 locus, with significantly different allelic effects between the Japanese and Scottish populations ($P = 0.001$) (Fig. 2). The difference in genetic effects at rs3802842 between Europeans and Japanese remained significant ($P = 0.03$), even when we excluded Scottish phase 1 data to avoid potential bias.

We did not find any evidence for gene-by-gene, sex, age, cancer stage, family history or cohort interactions (Supplementary Tables 6 and 7 online) with rs7014346, rs4939827 or rs3802842 in the populations of European ancestry. However, there were notable site-specific differences in risk associated with the 11q23 locus (rs3802842; $P < 0.008$) and the *SMAD7* locus at 18q21 (rs4939827; $P < 0.009$) (Table 3 and Supplementary Fig. 8 online). The risk of rectal cancer was greater than for colonic cancer for both rs3802842 and rs4939827. It should also be noted that the differential effect on colon cancer risk and rectal cancer risk explains much of the population differences between Japanese and Caucasian populations for rs3802842, with colon cancer risk in particular driving the population difference.

Genome-wide association studies are beginning to unravel the genetic architecture underlying complex disease traits. In this study, we identify a previously unreported locus on 11q23, tagged by rs3802842, which is associated with CRC. Extending the previous observations made by ourselves[4] and others[5,6] at the chromosome 8q24 locus and at the *SMAD7* locus[7] on 18q21, we have fine mapped and further replicated these two associations, showing consistent effects across multi-ethnic populations. The variants are common in the general population, with risk allele frequencies in populations of European ancestry of 0.29, 0.37 and 0.52 for rs3802842, rs7014346 and rs4939827, respectively. The population attributable risks (PAR) in the Scottish population are estimated to be 6.5%, 9.6% and 3.3% for rs7014346, rs4939827 and rs3802842,

respectively. In the Japanese population, the PAR was estimated to be 4.4% for rs 7014346 and 4% for rs4939827, primarily as a result of differences in allele frequency.

The observation that rs3802842 is associated with significantly different risk in Japanese compared to European samples is the first evidence for a population-specific CRC susceptibility allele. It is particularly noteworthy that the population difference is site-specific. The Japanese population does not show the increased risk of colonic cancer associated with rs3802842 that is observed in European populations, but it does show a similar risk of rectal cancer at that locus.

Although we urge caution in implementing models for predicting individual risk, such approaches incorporating multilocus genotypes could help identify high-risk subgroups within populations. Thus, for individuals who carry all six possible risk alleles at rs7014346, rs4939827 and rs3802842 (population frequency 0.005), the estimated OR is 2.6 (95% CI = 1.75-3.89). This underscores the potential for future risk profiling, even without identification of the causative variant[12]. However, large multinational cohort studies will be needed to validate such genetic risk predictive models.

In the context of genome-wide association studies, it is note-worthy that the associations that replicated across populations (rs7014346, rs4939827 and rs3802842) were ranked 449, 5,965 and 11,064 in our initial scan, respectively. Hence, follow-up of the 2.7% of putative associations from phase 1 seems appropriate. Some modeling suggests that a lower proportion taken forward to phase 2 is sufficient (<1%)[13], but power to distinguish true from false positives using available tools (see URLs section below) may be overestimated. Study design for genome-wide scans is evolving and, as costs reduce, genotyping of large numbers of markers in large sample sets and avoiding phased designs altogether would be an ideal approach.

As well as providing risk estimates for population groups, identification of these loci provides new insights into disease causation. Despite extensive resequencing, we did not identify causative coding sequence variants in any of the genes at 8q24 (*POU5F1P1, HsG57825* and *DQ515897*) or 18q21 (*SMAD7*). It seems likely that regulatory sequence variants or position effects underlie the associations detected here. Studies of the mechanisms by which these genetic associations impart CRC risk could inform the development of small molecule interventions for chemoprevention and chemotherapy.

## METHODS

### Study populations and genotyping

Phase 1 and 2 samples were collected in a prospective population-based study in Scotland (1999-2006). Cases were recruited soon after confirmed diagnosis of adenocarcinoma of large bowel (phase 1, aged ≤55 years; phase 2, aged <80 years), We genotyped individuals in phase 1 using Illumina HumanHap300 and HumanHap240S arrays on the Infinium platform, and we genotyped individuals in phase 2 using the Illumina iSelect custom panel. For individuals in phase 3 (described in **Supplementary Methods** online), we used Applied Biosystems (ABI) TaqMan assays exclusively to genotype subjects from the Scottish, English, German, Israeli and Spanish populations, TaqMan and Sequenom technologies for the Canadian samples and Invader assays for the Japanese samples. Call rates and departures from Hardy-Weinberg equilibrium (HWE) in control populations are shown in Supplementary Table 4, and quality control measures are described in the **Supplementary Note.**

### Statistical methods

We analyzed phase 1 data using a likelihood ratio test (LRT) with 2 degrees of freedom (d.f.) to account for an additive and a dominant effect. Although we tested all SNPs under an allelic

model, we did not use this for phase 2 SNP selection. Chromosome X SNPs were tested only with 2 d.f. in females and with 1 d.f. when combining male and female samples. We used only LRT statistics from females to select phase 2 SNPs. The mitochondrial and Y chromosome SNPs were tested with 1 d.f. and 2 d.f., respectively. Although only the first is strictly appropriate, only LRT with 2 d.f. was used as the selection criteria in phase 1. Thus, we applied more stringent selection criteria for selecting phase 2 SNPs on chromosome X, Y and mitochondrial DNA than for autosomal regions. Our approach to estimation of the false discovery rate and permutation testing to assess genome-wide and chromosome-wise empirical significant thresholds are both described in **Supplementary Methods.**

### Testing differences in effects among populations

To test whether two different populations had different OR for a given SNP, we used a standar *t*-test on the natural log transformation of the ORs. Under asymptotic assumptions, the lnOR is normally distributed with mean lnOR and variance ($\sigma^2_{\mathrm{lnOR}}$). The statistic

$T = (\ln OR_1 - \ln OR_2) / \left( \sigma^2_{\mathrm{lnOR1}} + \sigma^2_{\mathrm{lnOR2}} \right)^{1/2}$, where 1 and 2 indicate the two different populations, can be assumed to be normally distributed for large sample sizes.

### Meta-analysis

We carried out the meta-analysis using the metabin option from the meta package of the R software. We used the Mantel-Haenszel method to estimate pooled allelic effects under a fixed effect model when there was not significant heterogeneity ($P_{\mathrm{Het}} < 0.05$). If there was significant heterogeneity, then we used a random effects model and the DerSimonian-Laird method. The OR was used as the summary measure. As we had used a genotypic model to select phase 3 SNPs, we also tested the same genetic model using logistic regression (fitting age, gender, sample set and genotype) on all but the Japanese case-control set, for which the raw phenotypic data was not available because of internal regulations in Japan. Nested models with and without the genotypes were compared using an analysis of deviance. Interaction terms were tested in the same fashion.

### Fine mapping

LD plots for the 8q24, 18q21 and 11q23 regions are shown in Supplementary Figure 6. Detail on fine-mapping methodology is presented in **Supplementary Methods.** Briefly, we selected fine-mapping SNPs for the 8q24 and 18q21 regions using Phase 2 HapMap CEU data[14]. Haploview[15] was used to select SNPs to tag ($r^2 = 1$, MAF threshold = 0.00001) from all HapMap CEU SNPs between chromosome 8 positions 128426625 and 128543974 (50 kb centromeric of rs10505477 (ref. [4]) and 50 kb telomeric of rs7014346). Including additional selected SNPs, there were 94 SNPs that successfully genotyped in 4,116 Scottish samples to tag 131 alleles at $r^2 \geq 0.8$ (mean maximum $r^2 = 0.999$) using Haploview 4.0 tagger[15]. For 18q21, we selected SNPs from the interval between positions 44657461 and 44757927 (50 kb on either side of the interval between rs4939827 and rs12953717) and successfully genotyped 51 SNPs in 4,116 Scottish samples, tagging 64 alleles at $r^2 \geq 0.8$ (mean maximum $r^2 = 1$) (Haploview 4.0 tagger). The 11q23 locus could not be formally fine mapped. However, as it encompasses a gene encoding a POU transcription gene family member (*POU2AF1*), we selected the six top-ranked SNPs < 100 kb from *POU2AF1* and two SNPs located within the *POU2AF1* gene itself. For further analysis, we used this genotyping data and HapMap data in the program IMPUTE[11]. We used genotyping data from phase 1 individuals along with HapMap data to estimate genotypes for SNPs that we did not genotype. SNPTEST was used to test for genotype-phenotype associations under a genotypic model. Details on IMPUTE and SNPTEST are presented in **Supplementary Methods.**

### Resequencing, gene expression, tumor LOH and immunohistochemistry

Resequencing focused on regions at the 8q24 and 18q21 loci delineated by fine mapping and IMPUTE analysis. For 8q24 locus, there are three putative genes: *POU5FIP1, HsG57825* and *DQ515897*. As *POU5FIP1* is highly homologous to other POU genes, we designed chromosome 8-specific primers for all coding regions using a combination of primer design packages available through the University of California Santa Cruz and Primer3 **(Supplementary Methods)**. Amplicons were sequenced and analyzed as described[16] in 168 individuals (78 cases, 90 controls). Published expression data are available[5], and we also found that *POU5F1P1* is transcribed in blood leukocytes and colonic epithelium (data not shown). The associated SNPs at the chromosome 18q21 locus were both located within the genomic structure of *SMAD7*. Hence, we resequenced only exons and intron-exon boundaries of *SMAD7* in 256 individuals (166 cases and 90 controls). Available annotation and expression data for 8q24 and 18q21 gene are described in **Supplementary Methods.**

We carried out LOH analysis in CRCs from up to 43 individuals heterozygous at rs7014346, rs4939827 and rs3802842, as well as the CA repeat marker, D18S58, at the 18q21 locus. LOH was assessed in relation to the risk allele. Tumor immunohistochemistry was done as described[2] with minor modifications in 40 tumor and normal samples for which genotypes at rs7014346, rs4939827 and rs3802842 were previously defined.

## References

1. Lichtenstein P, et al. Enviornmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med 2000;343:78–85. [PubMed: 10891514]

2. Barnetson RA, et al. Identification and survival of carriers of multations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med 2006;354:2751–2763. [PubMed: 16807412]

3. Tenesa A, et al. Association of MUTYH and colorectal cancer. Br. J. Cancer 2006;95:239–242. [PubMed: 16804517]

4. Zanke BW, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet 2007;39:989–994. [PubMed: 17618283]

5. Tomlinson I, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet 2007;39:984–988. [PubMed: 17618284]

6. Haiman CA, et al. A common genetic risk factor for colorectal and prostate cancer. Nat. Genet 2007;39:954–956. [PubMed: 17618282]

7. Broderick P, et al. A genome-wide association study shows that common alleles of *SMAD7* influence colorectal cancer risk. Nat. Genet 2007;39:1315–1317. [PubMed: 17934461]

8. Sokal, RR.; Rohlf, FJ. Biometry: the principles and Practice of Statistics in Biological Research. Vol. 3rd edn. W.H. Freeman and Co.; New York: 1995.

9. Churchill GA, Doerge RW. Empirical threshold values for quantitative trait mapping. Genetics 1994;138:963–971. [PubMed: 7851788]

10. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 2003;100:9440–9445. [PubMed: 12883005]

11. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet 2007;39:906–913. [PubMed: 17572673]

12. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res 2007;17:1520–1528. [PubMed: 17785532]

13. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet 2006;38:209–213. [PubMed: 16415888]

14. Tenesa A, Dunlop MG. Validity of tagging SNPs across populations for association studies. Eur. J. Hum. Genet 2006;14:357–363. [PubMed: 16391562]

15. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–265. [PubMed: 15297300]

16. Farrington SM, et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am. J. Hum. Genet 2005;77:112–119. [PubMed: 15931596]

**Figure 1.**
Fine mapping of the 8q24 and 18q23 (*SMAD7*) loci. Graphs show -log₁₀*P* against distance. Black dots correspond to the analysis of data generated from phase 1 and 2 individuals. Red dots are from the analysis of data from phase 2 individuals. rsIDS are provided for the SNPs with peak evidence for association. These fine mapping data are further informed by results shown in Supplementary Figure 7 from IMPUTE and SNPTEST analysis of the loci on chromosomes 8q, 18q and 11q.

**Figure 2.**
Forest plot of effect size and direction for each of the three SNPs associated with CRC (rs7014346, rs4939827 and rs3802842). Symbol size indicates the weight of the study in the fixed effect model (the larger the symbol, the greater the weight), as in the output from the program R. rs3802842 was stratified by ethnic group, because most of the heterogeneity observed was due to differences between GWAS data from the Scottish and the Japanese populations.

**Table 1**

**Smaples genotyped in phases 1, 2 and 3 from all populations**

|  | Population | Cases | Controls | Total |
|---|---|---|---|---|
| Scotland GWAS | Scotland, phase 1 | 981 | 1,002 | 1,983 |
|  | Scotland, phase 2 | 2,023 | 2,092 | 4,115 |
|  | Total GWAS | 3,004 | 3,094 | 6,098 |
| Replication | Canada | 1,175 | 1,184 | 2,359 |
|  | DACHS | 1,373 | 1,480 | 2,853 |
|  | England | 2,253 | 2,262 | 4,515 |
|  | Israel | 1,789 | 1,771 | 3,560 |
|  | Japan | 4,400 | 3,179 | 7,579 |
|  | Kiel | 2,169 | 2,145 | 4,314 |
|  | Scotland Replication | 937 | 941 | 1,878 |
|  | Spain | 357 | 297 | 654 |
|  | Total Replication | 14,453 | 13,259 | 27,712 |
| Total samples |  | 17, 457 | 16,353 | 33,810 |

**Table 2**

**SNPs genotyped in phase 3 and summary description from the meta-analysis of all available data**

| SNP | Rank | Chr. | Position | Variant | All samples | | | | | | Replication samples | | | | | | Replication samples of European ancestry | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | | | Number of sets | $P_{het}{}^{a}$ | $I^2$ (%) | Effects model | P | OR (95% CI) | Number of sets | $P_{het}{}^{a}$ | $I^2$ (%) | Effects model | P | OR (95% CI) | Number of sets | $P_{het}{}^{a}$ | $I^2$ (%) | Effects model | P | OR (95% CI) |
| rs6533603[b] | 3 | 4 | 113440251 | T | 9 | 0.001 | 68 | Random | 0.81 | 1.01 (0.95–1.07) | 8 | 0.36 | 9 | Fixed | 0.21 | 0.98 (0.94–1.01) | 7 | 0.44 | 0 | Fixed | 0.48 | 0.99 (0.95–1.03) |
| rs7014346[b] | 1 | 8 | 128493974 | A | 9 | 0.343 | 11 | Fixed | $8.60 \times 10^{-26}$ | 1.19 (1.15–1.23) | 8 | 0.26 | 21 | Fixed | $1.85 \times 10^{-20}$ | 1.19 (1.14–1.23) | 7 | 0.18 | 32 | Fixed | $4.44 \times 10^{-16}$ | 1.19 (1.14–1.24) |
| rs7842552 | | 8 | 128800876 | G | 8 | 0.026 | 56 | Random | $1.20 \times 10^{-5}$ | 1.15 (1.08–1.23) | 7 | 0.02 | 59 | Random | $4.48 \times 10^{-4}$ | 1.14 (1.06–1.23) | 6 | 0.01 | 65 | Random | $1.85 \times 10^{-3}$ | 1.15 (1.05–1.25) |
| rs1213809 | 4 | 11 | 110640955 | A | 8 | 0.086 | 43 | Fixed | $7.93 \times 10^{-8}$ | 1.11 (1.07–1.16) | 7 | 0.29 | 18 | Fixed | $6.79 \times 10^{-4}$ | 1.08 (1.03–1.13) | 6 | 0.34 | 11 | Fixed | $2.98 \times 10^{-4}$ | 1.09 (1.04–1.14) |
| rs3802842[b] | | 11 | 110676919 | C | 9 | 0.050 | 48 | Fixed | $5.82 \times 10^{-10}$ | 1.11 (1.08–1.15) | 8 | 0.18 | 32 | Fixed | $5.54 \times 10^{-6}$ | 1.09 (1.05–1.13) | 7 | 0.43 | 0 | Fixed | $7.82 \times 10^{-7}$ | 1.12 (1.07–1.17) |
| rs7947952 | | 11 | 110686330 | T | 3 | 0.081 | 60 | Fixed | 0.04 | 1.06 (1.00–1.11) | 2 | 0.12 | 58 | Fixed | 0.81 | 1.01 (0.94–1.09) | 1 | - | - | - | 0.19 | 1.08 (0.96–1.21) |
| rs10749971 | | 11 | 110694368 | G | 8 | 0.818 | 0 | Fixed | $6.71 \times 10^{-6}$ | 1.09 (1.05–1.13) | 7 | 0.86 | 0 | Fixed | $9.46 \times 10^{-4}$ | 1.08 (1.03–1.13) | 6 | 0.83 | 0 | Fixed | $7.67 \times 10^{-4}$ | 1.08 (1.03–1.13) |
| rs4514461 | | 11 | 110732153 | A | 8 | 0.072 | 46 | Fixed | $7.90 \times 10^{-3}$ | 1.05 (1.01–1.09) | 7 | 0.20 | 30 | Fixed | 0.19 | 1.03 (0.99–1.07) | 6 | 0.21 | 30 | Fixed | 0.096 | 1.04 (0.99–1.09) |
| rs12799202 | | 11 | 110749966 | G | 8 | 0.533 | 0 | Fixed | $4.98 \times 10^{-4}$ | 1.07 (1.03–1.12) | 7 | 0.55 | 0 | Fixed | 0.01 | 1.06 (1.01–1.11) | 6 | 0.73 | 0 | Fixed | 0.003 | 1.08 (1.03–1.14) |
| rs4939827[b] | 2 | 18 | 44707461 | T | 9 | 0.336 | 12 | Fixed | $7.77 \times 10^{-28}$ | 1.20 (1.16–1.24) | 8 | 0.25 | 22 | Fixed | $4.38 \times 10^{-23}$ | 1.20 (1.16–1.24) | 7 | 0.17 | 33 | Fixed | $8.70 \times 10^{-19}$ | 1.20 (1.15–1.25) |
| rs12953717 | | 18 | 44707927 | T | 4 | 0.964 | 0 | Fixed | $3.10 \times 10^{-11}$ | 1.18 (1.12–1.23) | 3 | 0.93 | 0 | Fixed | $2.07 \times 10^{-7}$ | 1.18 (1.11–1.26) | 2 | 0.71 | 0 | Fixed | 0.002 | 1.18 (1.06–1.30) |
| rs9951602[b] | 5 | 18 | 74758767 | T | 9 | 0.059 | 47 | Fixed | 0.44 | 1.02 (0.97–1.07) | 8 | 0.04 | 53 | Random | 0.64 | 1.02 (0.94–1.10) | 7 | 0.03 | 56 | Random | 0.51 | 1.03 (0.94–1.13) |

The Mantel-Haenszel method was used.

[a] When there was no significant heterogeneity ($P_{het} > 0.05$), the Mantel-Haenszel method was used to estimate pooled allelic effects under a fixed effect model, A random effects model, the DerSimonian-Laird method, was used if there was significant heterogeneity.

[b] SNPs identified through the GWAS.

**Table 3**

**Meta-analysis of differences between colon and rectal cancer risk using data from all nine sample sets**

| | SNP rsID | Reference allele | Fixed effects model | | | Random effects model | | | Heterogeneity | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | OR | 95% CI | P | OR | 95% CI | P | $I^2$ | P |
| Colon vs. Rectal | rs7014346 | A | 1.025 | 0.976-1.077 | 0.316 | 1.025 | 0.976-1.077 | 0.319 | 0.000 | 0.461 |
| | rs4939827 | C | 1.068 | 1.017-1.123 | 0.009 | 1.068 | 1.017-1.123 | 0.009 | 0.000 | 0.566 |
| | rs3802842 | A | 1.070 | 1.018-1.126 | 0.008 | 1.070 | 1.018-1.126 | 0.008 | 0.000 | 0.822 |
| Colon vs. Controls | rs7014346 | A | 1.200 | 1.156-1.247 | $<10^{-15}$ | 1.201 | 1.156-1.247 | $<10^{-15}$ | 0.000 | 0.742 |
| | rs4939827 | T | 1.169 | 1.125-1.1214 | $1.11 \times 10^{-15}$ | 1.169 | 1.125-1.214 | $1.11 \times 10^{-15}$ | 0.000 | 0.583 |
| | rs3802842 | C | 1.088 | 1.046-1.132 | $10^{-15}$ | 1.097 | 1.030-1.169 | $3.90 \times 10^{-3}$ | 55.87 | 0.020 |
| Rectal vs. Controls | res7014346 | A | 1.175 | 1.123-1.229 | $2.53 \times 10^{-2}$ | 1.166 | 1.094-1.244 | $2.83 \times 10^{-6}$ | 45.67 | 0.065 |
| | rs4939827 | T | 1.253 | 1.198-1.311 | $<10^{-15}$ | 1.253 | 1.198-1.311 | $<10^{-15}$ | 0.000 | 0.842 |
| | rs3802842 | C | 1.163 | 1.110-1.218 | $1.98 \times 10^{-10}$ | 1.163 | 1.110-1.219 | $1.87 \times 10^{-10}$ | 0.000 | 0.877 |

Forest plots are shown in Supplementary Figure 9 online. For clarity of comparison, the reference alleles for colon versus rectal cancer risk are set to allow presentation of ORs in the same direction across all analyses.